Immuno-Oncology Summit Europe 2024: April 23-25
Visit Our Bispecific Antibody Poster at IO Summit Europe 2024!
Biocytogen’s antibody Business Development & Licensing team is excited to attend the upcoming Immuno-Oncology Summit Europe 2024 conference, set to take place in London, UK, from April 23-25, 2024! During the event, our team will present a poster, titled “Fully human conditional agonist 4-1BB x CD40 bispecific antibody exhibits potent in vitro and in vivo efficacy”. Our novel 4-1BB x CD40 bispecific antibody (BCG021) significantly enhanced the in vivo anti-tumor efficacy of anti-PD-1 monoclonal antibody therapy. Furthermore, preclinical studies in mouse models indicated a favorable safety profile for BCG021.
Bispecific antibodies offer novel therapeutic mechanisms, distinct from monotherapies and combination therapies. They offer conditional activation or precise targeting of the tumor microenvironment to mitigate systemic toxicity. Additionally, bispecific antibodies provide dual blockade abilities, effectively addressing drug resistance concerns.
To facilitate the development of bispecific antibodies, Biocytogen has developed RenLite® mice capable of generating fully human common light chain antibodies, which serve as building blocks for constructing Y-shaped bispecific antibodies. Using this strategy, we have developed numerous bispecific antibodies including, a CTLA-4 x OX40 bsAb for oncology and an OX40 biparatopic bsAb for autoimmune diseases.
We look forward to exploring partnership opportunities with you for our antibody-based assets or antibody discovery platforms! For questions, please contact [email protected].
Poster Information
Poster Title: Fully Human Conditional Agonist 4-1BB×CD40 Bispecific Antibody Exhibits Potent In Vitro and In Vivo Efficacy
Poster Session: Session B
Date/Time: April 24, 2024
Now into the 8th year, CHI’s Immuno-Oncology Summit Europe is the premier event for immuno-oncology professionals who want to learn about the latest advancements and innovations in the field. The Summit will take place on 23-25 April 2024 in London, one of the world’s leading hubs for biomedical research and clinical development. (Source: Immuno-Oncology Summit Europe)
Event Date: April 23-25, 2024 | Event Location: London, UK
